However, grade 3–4 neutropenia was observed in 74% of patients and other side effects, in particular peripheral neuropathies were also frequently observed.55 A phase III trial of bevacizumab plus IFN-α versus IFN-α monotherapy in patients with metastatic renal cell carcinoma showed that the median overall survival time was 18.3 months for bevacizumab plus IFN-α group and 17.4 months for the IFN-α monotherapy group, but there was significantly more grade 3–4 hypertension, anorexia, fatigue, and proteinuria for the bevacizumab plus IFN-α group.56 The gene discussed is IFNA1; the disease is hypertensive disorder.